German pharmaceutical and life sciences company Bayer AG (ETR:BAYN) (OTC:BAYRY) announced on Wednesday a strategic partnership with biotechnology company NextRNA Therapeutics to develop small molecule drugs targeting long non-coding RNAs (lncRNAs) in oncology.
LncRNAs play a crucial role in various diseases, including cancer, making them promising therapeutic targets.
The collaboration will focus on two oncology programmes in high unmet need indications. NextRNA will provide the initial target for the first programme, while the second will involve Bayer selecting a target identified by NextRNA's platform. NextRNA will receive up to USD547m in potential payments, including upfront, milestone and royalty payments, as well as tiered royalties on net sales.
NeoGenomics to present breakthrough data at ESMO 2024 on ctDNA and NGS for cancer diagnostics
Pheon Therapeutics names new independent, non-executive director
Solu Therapeutics names new chief medical officer
Carisma and Moderna expand collaboration
OSE Immunotherapeutics initiates Phase 3 trial for cancer vaccine Tedopi
Phanes Therapeutics doses first subject in clinical study of PT886 in combination with chemotherapy
AbbVie advances solid tumour pipeline with new data at ESMO 2024
Amgen showcases promising data for IMDELLTRA in small cell lung cancer at WCLC 2024
Cantargia reports promising data for nadunolimab in cancer treatment
Hemogenyx Pharmaceuticals announces readiness of FLT3 assay for Phase I Trials at MD Anderson
Avacta announces presentation of updated data on AVA6000 at ESMO Congress 2024